Sinopharm Announces Beijing Approval of COVID-19 Vaccine Trials

Pfizer PFE $51.6 -1,47% Buy Moderna MRNA$176.73 +0.48% Buy Johnson &Johnson JNJ $177.64 -1,11% Buy

China National Pharmaceutical Group (a division of Sinopharm) said its second-generation COVID-19 vaccine has received Beijing's approval for clinical trials. It is reported by Bloomberg.

There is currently a new outbreak in China. More than 13,000 new cases of COVID-19 have been reported today. The authorities of Shanghai, which is located in the eastern part of China , have decided to close the city from March 28.

Follow the news of the companies in the telegram channel "Catalog of RBC Investments"

Read together with it: